Showing results (371-380 of 399) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remissionA R Zander, C Berger, N Kröger, et al.
Blood|October 7, 2006
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantationDjordje Atanackovic, Julia Arfsten, Yanran Cao, et al.
Cancer|December 12, 1997
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in LeukemiaC D Bloomfield, C Shuma, L Regal, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Blood|October 2, 2004
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseWalter Fiedler, Hubert Serve, Hartmut Döhner, et al.
Blood|September 10, 1998
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89W D Ludwig, H Rieder, C R Bartram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemiaRüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2007
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study GroupG Ryan, G Martinelli, M Kuper-Hommel, et al.
Pageof 40